{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:13:53Z","timestamp":1792653233276,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,9]],"date-time":"2019-03-09T00:00:00Z","timestamp":1552089600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006254","name":"Ruhr-Universit\u00e4t Bochum","doi-asserted-by":"publisher","award":["Forum"],"award-info":[{"award-number":["Forum"]}],"id":[{"id":"10.13039\/501100006254","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12974-019-1445-0","type":"journal-article","created":{"date-parts":[[2019,3,9]],"date-time":"2019-03-09T07:02:36Z","timestamp":1552114956000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Intrathecal triamcinolone acetonide exerts anti-inflammatory effects on Lewis rat experimental autoimmune neuritis and direct anti-oxidative effects on Schwann cells"],"prefix":"10.1186","volume":"16","author":[{"given":"Kalliopi","family":"Pitarokoili","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Sgodzai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Gr\u00fcter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein","family":"Bachir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremias","family":"Motte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Ambrosius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiomara","family":"Pedreiturria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Suk","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,9]]},"reference":[{"issue":"12","key":"1445_CR1","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1097\/IAE.0000000000000726","volume":"35","author":"Y Yang","year":"2015","unstructured":"Yang Y, Bailey C, Loewenstein A, Massin P. Intravitreal corticosteroids in diabetic macular edema: pharmacokinetic considerations. Retina. 2015;35(12):2440\u20139.","journal-title":"Retina."},{"key":"1445_CR2","doi-asserted-by":"publisher","first-page":"8640970","DOI":"10.1155\/2017\/8640970","volume":"2017","author":"KM Madalena","year":"2017","unstructured":"Madalena KM, Lerch JK. The effect of glucocorticoid and glucocorticoid receptor interactions on brain, spinal cord, and glial cell plasticity. Neural Plast. 2017;2017:8640970.","journal-title":"Neural Plast"},{"issue":"1","key":"1445_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1471-2377-4-18","volume":"4","author":"K Hellwig","year":"2004","unstructured":"Hellwig K, Stein FJ, Przuntek H, M\u00fcller T. Efficacy of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients with spinal symptoms. BMC Neurol. 2004;4(1):18.","journal-title":"BMC Neurol"},{"issue":"9","key":"1445_CR4","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1586\/ern.09.60","volume":"9","author":"T M\u00fcller","year":"2009","unstructured":"M\u00fcller T. Role of intraspinal steroid application in patients with multiple sclerosis. Expert Rev Neurother. 2009;9(9):1279\u201387.","journal-title":"Expert Rev Neurother"},{"issue":"1","key":"1445_CR5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/j.1468-1331.2006.01145.x","volume":"13","author":"V Hoffmann","year":"2006","unstructured":"Hoffmann V, Kuhn W, Schimrigk S, Islamova S, Hellwig K, Lukas C, Brune N, P\u00f6hlau D, Przuntek H, M\u00fcller T. Repeat intrathecal triamcinolone acetonide application is beneficial in progressive MS patients. Eur J Neurol. 2006;13(1):72\u20136.","journal-title":"Eur J Neurol"},{"issue":"1","key":"1445_CR6","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/WNF.0000000000000015","volume":"37","author":"T M\u00fcller","year":"2014","unstructured":"M\u00fcller T, Herrling T, L\u00fctge S, K\u00fcchler M, Lohse L, Rothe H, Haas T, Marg M, \u00d6hm G, Jung K. Reduction in the free radical status and clinical benefit of repeated intrathecal triamcinolone acetonide application in patients with progressive multiple sclerosis. Clin Neuropharmacol. 2014;37(1):22\u20135.","journal-title":"Clin Neuropharmacol"},{"issue":"3","key":"1445_CR7","doi-asserted-by":"publisher","first-page":"377","DOI":"10.4103\/1673-5374.153682","volume":"10","author":"T M\u00fcller","year":"2015","unstructured":"M\u00fcller T, L\u00fctge S. Biochemical indicators for neuronal regeneration during intrathecal triamcinolone application in multiple sclerosis. Neural Regen Res. 2015;10(3):377\u20139.","journal-title":"Neural Regen Res"},{"issue":"2","key":"1445_CR8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/sc.2014.155","volume":"53","author":"F Kamin","year":"2015","unstructured":"Kamin F, Rommer PS, Abu-Mugheisib M, Koehler W, Hoffmann F, Winkelmann A, Benecke R, Zettl UK. Effects of intrathecal triamincinolone-acetonide treatment in MS patients with therapy-resistant spasticity. Spinal Cord. 2015;53(2):109\u201313.","journal-title":"Spinal Cord"},{"issue":"1","key":"1445_CR9","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/cns.12474","volume":"22","author":"PS Rommer","year":"2016","unstructured":"Rommer PS, Kamin F, Abu-Mugheisib M, Koehler W, Hoffmann F, Winkelmann A, Benecke R, Zettl UK. Long-term effects of repeated cycles of intrathecal triamcinolone acetonide on spasticity in MS patients. CNS Neurosci Ther. 2016;22(1):74\u20139.","journal-title":"CNS Neurosci Ther"},{"key":"1445_CR10","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jneuroim.2017.05.008","volume":"309","author":"K Pitarokoili","year":"2017","unstructured":"Pitarokoili K, Kohle F, Motte J, Fatoba O, Pedreiturria X, Gold R, Yoon MS. Anti-inflammatory and immunomodulatory potential of human immunoglobulin applied intrathecally in Lewis rat experimental autoimmune neuritis. J Neuroimmunol. 2017;309:58\u201367.","journal-title":"J Neuroimmunol"},{"key":"1445_CR11","doi-asserted-by":"crossref","unstructured":"Hughes RA, Pritchard J, Hadden RD. Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barr\u00e9 syndrome. Cochrane Database Syst Rev. 2013;28;(2):CD008630.","DOI":"10.1002\/14651858.CD008630.pub3"},{"issue":"1\u20132","key":"1445_CR12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jns.2014.02.019","volume":"340","author":"A Kerasnoudis","year":"2014","unstructured":"Kerasnoudis A, Pitarokoili K, Behrendt V, Gold R, Yoon MS. Increased cerebrospinal fluid protein and motor conduction studies as prognostic markers of outcome and nerve ultrasound changes in Guillain-Barr\u00e9 syndrome. J Neurol Sci. 2014;340(1\u20132):37\u201343.","journal-title":"J Neurol Sci"},{"issue":"4","key":"1445_CR13","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S0301-0082(01)00012-0","volume":"65","author":"GB Makara","year":"2001","unstructured":"Makara GB, Haller J. Non-genomic effects of glucocorticoids in the neural system. Evidence, mechanisms and implications. Prog Neurobiol. 2001;65(4):367\u201390.","journal-title":"Prog Neurobiol"},{"issue":"12","key":"1445_CR14","doi-asserted-by":"publisher","first-page":"5549","DOI":"10.1210\/en.2006-0981","volume":"147","author":"JG Tasker","year":"2006","unstructured":"Tasker JG, Di S, Malcher-Lopes R. Minireview: rapid glucocorticoid signaling via membrane-associated receptors. Endocrinology. 2006;147(12):5549\u201356 Epub 2006 Aug 31. Review.","journal-title":"Endocrinology"},{"issue":"4","key":"1445_CR15","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/jcbfm.2009.243","volume":"30","author":"SL Goericke","year":"2010","unstructured":"Goericke SL, Engelhorn T, Forsting M, Speck U, Maderwald S, Ladd ME, Doerfler A. Intrathecal corticoids in permanent focal cerebral ischemia in rats. Part I: a new therapeutic approach in the acute phase. J Cereb Blood Flow Metab. 2010;30(4):801\u20137.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"Pt 7","key":"1445_CR16","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1093\/brain\/121.7.1257","volume":"121","author":"U Enders","year":"1998","unstructured":"Enders U, Lobb R, Pepinsky RB, Hartung HP, Toyka KV, Gold R. The role of the very late antigen-4 and its counterligand vascular cell adhesion molecule-1 in the pathogenesis of experimental autoimmune neuritis of the Lewis rat. Brain. 1998;121(Pt 7):1257\u201366.","journal-title":"Brain."},{"issue":"8","key":"1445_CR17","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/S0169-409X(03)00101-7","volume":"55","author":"CA Fairbanks","year":"2003","unstructured":"Fairbanks CA. Spinal delivery of analgesics in experimental models of pain and analgesia. Adv Drug Deliv Rev. 2003;55(8):1007\u201341 Review.","journal-title":"Adv Drug Deliv Rev"},{"issue":"2\u20133","key":"1445_CR18","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/0022-510X(82)90140-X","volume":"56","author":"RR Tuck","year":"1982","unstructured":"Tuck RR, Antony JH, McLeod JG. F-wave in experimental allergic neuritis. J Neurol Sci. 1982;56(2\u20133):173\u201384.","journal-title":"J Neurol Sci"},{"issue":"3","key":"1445_CR19","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/mus.10432","volume":"28","author":"JM Taylor","year":"2003","unstructured":"Taylor JM, Pollard JD. Neurophysiological changes in demyelinating and axonal forms of acute experimental autoimmune neuritis in the Lewis rat. Muscle Nerve. 2003;28(3):344\u201352.","journal-title":"Muscle Nerve"},{"key":"1445_CR20","doi-asserted-by":"publisher","first-page":"31781","DOI":"10.1038\/srep31781","volume":"6","author":"ND Andersen","year":"2016","unstructured":"Andersen ND, Srinivas S, Pi\u00f1ero G, Monje PV. A rapid and versatile method for the isolation, purification and cryogenic storage of Schwann cells from adult rodent nerves. Sci Rep. 2016;6:31781.","journal-title":"Sci Rep"},{"issue":"1","key":"1445_CR21","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1006\/cimm.1995.1187","volume":"165","author":"R Gold","year":"1995","unstructured":"Gold R, Toyka KV, Hartung HP. Synergistic effect of IFN-gamma and TNF-alpha on expression of immune molecules and antigen presentation by Schwann cells. Cell Immunol. 1995;165(1):65\u201370.","journal-title":"Cell Immunol"},{"issue":"9","key":"1445_CR22","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1093\/nar\/29.9.e45","volume":"29","author":"MW Pfaffl","year":"2001","unstructured":"Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29(9):e45.","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"1445_CR23","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1016\/j.celrep.2015.02.048","volume":"10","author":"E Demicheva","year":"2015","unstructured":"Demicheva E, Cui YF, Bardwell P, Barghorn S, Kron M, Meyer AH, Schmidt M, Gerlach B, Leddy M, Barlow E, O'Connor E, Choi CH, Huang L, Veldman GM, Rus H, Shabanzadeh AP, Tassew NG, Monnier PP, M\u00fcller T, Calabresi PA, Schoemaker H, Mueller BK. Targeting repulsive guidance molecule A to promote regeneration and neuroprotection in multiple sclerosis. Cell Rep. 2015;10(11):1887\u201398.","journal-title":"Cell Rep"},{"issue":"4","key":"1445_CR24","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1254\/jphs.FP0072181","volume":"106","author":"R Hayashi","year":"2008","unstructured":"Hayashi R, Xiao W, Kawamoto M, Yuge O, Bennett GJ. Systemic glucocorticoid therapy reduces pain and the number of endoneurial tumor necrosis factor-alpha (TNFalpha)-positive mast cells in rats with a painful peripheral neuropathy. J Pharmacol Sci. 2008;106(4):559\u201365 Epub 2008 Apr 3.","journal-title":"J Pharmacol Sci"},{"issue":"8","key":"1445_CR25","doi-asserted-by":"publisher","first-page":"e104205","DOI":"10.1371\/journal.pone.0104205","volume":"9","author":"F Shimizu","year":"2014","unstructured":"Shimizu F, Sawai S, Sano Y, Beppu M, Misawa S, Nishihara H, Koga M, Kuwabara S, Kanda T. Severity and patterns of blood-nerve barrier breakdown in patients with chronic inflammatory demyelinating polyradiculoneuropathy: correlations with clinical subtypes. PLoS One. 2014;9(8):e104205.","journal-title":"PLoS One"},{"issue":"Suppl 2","key":"1445_CR26","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1046\/j.1365-2036.1996.22164025.x","volume":"10","author":"R Brattsand","year":"1996","unstructured":"Brattsand R, Linden M. Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies. Aliment Pharmacol Ther. 1996;10(Suppl 2):81\u201390 discussion 91-2. Review.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"1445_CR27","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1002\/jnr.490380308","volume":"38","author":"TJ Neuberger","year":"1994","unstructured":"Neuberger TJ, Kalimi O, Regelson W, Kalimi M, De Vries GH. Glucocorticoids enhance the potency of Schwann cell mitogens. J Neurosci Res. 1994;38(3):300\u201313.","journal-title":"J Neurosci Res"},{"issue":"9","key":"1445_CR28","doi-asserted-by":"publisher","first-page":"4339","DOI":"10.1210\/en.2005-1625","volume":"147","author":"G Groyer","year":"2006","unstructured":"Groyer G, Eychenne B, Girard C, Rajkowski K, Schumacher M, Cadepond F. Expression and functional state of the corticosteroid receptors and 11 beta-hydroxysteroid dehydrogenase type 2 in Schwann cells. Endocrinology. 2006;147(9):4339\u201350.","journal-title":"Endocrinology."},{"issue":"18","key":"1445_CR29","doi-asserted-by":"publisher","first-page":"10459","DOI":"10.1073\/pnas.95.18.10459","volume":"95","author":"JR Chan","year":"1998","unstructured":"Chan JR, Phillips LJ 2nd, Glaser M. Glucocorticoids and progestins signal the initiation and enhance the rate of myelin formation. Proc Natl Acad Sci U S A. 1998;95(18):10459\u201364.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1445_CR30","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/S0006-8993(00)02130-2","volume":"865","author":"F D\u00e9sarnaud","year":"2000","unstructured":"D\u00e9sarnaud F, Bidichandani S, Patel PI, Baulieu EE, Schumacher M. Glucocorticosteroids stimulate the activity of the promoters of peripheral myelin protein-22 and protein zero genes in Schwann cells. Brain Res. 2000;865(1):12\u20136.","journal-title":"Brain Res"},{"issue":"8","key":"1445_CR31","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/glia.20977","volume":"58","author":"S Morisaki","year":"2010","unstructured":"Morisaki S, Nishi M, Fujiwara H, Oda R, Kawata M, Kubo T. Endogenous glucocorticoids improve myelination via Schwann cells after peripheral nerve injury: an in vivo study using a crush injury model. Glia. 2010;58(8):954\u201363.","journal-title":"Glia."},{"issue":"1","key":"1445_CR32","doi-asserted-by":"publisher","first-page":"11179","DOI":"10.1038\/s41598-018-28516-5","volume":"8","author":"H Zhang","year":"2018","unstructured":"Zhang H, Shao Z, Zhu Y, Shi L, Li Z, Hou R, Zhang C, Yao D. Toll-like receptor 4 (TLR4) expression affects Schwann cell behavior in vitro. Sci Rep. 2018;8(1):11179.","journal-title":"Sci Rep"},{"issue":"1","key":"1445_CR33","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0165-5728(01)00281-8","volume":"116","author":"DS Skundric","year":"2001","unstructured":"Skundric DS, Lisak RP, Rouhi M, Kieseier BC, Jung S, Hartung HP. Schwann cell-specific regulation of IL-1 and IL-1Ra during EAN: possible relevance for immune regulation at paranodal regions. J Neuroimmunol. 2001;116(1):74\u201382.","journal-title":"J Neuroimmunol"},{"issue":"4","key":"1445_CR34","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1177\/1756285616636551","volume":"9","author":"T M\u00fcller","year":"2016","unstructured":"M\u00fcller T, Herrling T, L\u00fctge S, Lohse L, \u00d6hm G, Jung K. One-time intrathecal triamcinolone acetonide application alters the redox potential in cerebrospinal fluid of progressive multiple sclerosis patients: a pilot study. Ther Adv Neurol Disord. 2016;9(4):264\u20138.","journal-title":"Ther Adv Neurol Disord"},{"issue":"6","key":"1445_CR35","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s40291-014-0114-3","volume":"18","author":"PS Rommer","year":"2014","unstructured":"Rommer PS, Kamin F, Petzold A, Tumani H, Abu-Mugheisib M, Koehler W, Hoffmann F, Winkelmann A, Benecke R, Zettl UK. Effects of repeated intrathecal triamcinolone-acetonide application on cerebrospinal fluid biomarkers of axonal damage and glial activity in multiple sclerosis patients. Mol Diagn Ther. 2014;18(6):631\u20137.","journal-title":"Mol Diagn Ther"},{"issue":"5","key":"1445_CR36","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1177\/1078155215600905","volume":"22","author":"R Olmos-Jim\u00e9nez","year":"2016","unstructured":"Olmos-Jim\u00e9nez R, Espuny-Mir\u00f3 A, D\u00edaz-Carrasco MS, Fern\u00e1ndez-Var\u00f3n E, Valderrey-Pulido M, C\u00e1rceles-Rodr\u00edguez C. Stability of four standardized preparations of methotrexate, cytarabine, and hydrocortisone for intrathecal use. J Oncol Pharm Pract. 2016;22(5):659\u201365.","journal-title":"J Oncol Pharm Pract"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-019-1445-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12974-019-1445-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-019-1445-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T17:15:36Z","timestamp":1721063736000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneuroinflammation.biomedcentral.com\/articles\/10.1186\/s12974-019-1445-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,9]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1445"],"URL":"https:\/\/doi.org\/10.1186\/s12974-019-1445-0","relation":{},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,9]]},"assertion":[{"value":"13 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All experiments were reviewed and approved by the North-Rhine-Westphalia, Germany authorities for animal experimentation (TVA 84-02.04.2017-A023).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Kalliopi Pitarokoili received travel funding and speaker honoraria from Biogen Idec, Novartis and Bayer Schering Pharma and funding from the Ruhr-University, Bochum (FORUM-Program). Thomas Gr\u00fcter received a travel reimbursement from Sanofi Genzyme and Biogen Idec, none related to this manuscript. Jeremias Motte received travel grants from Biogen Idec, none related to this work. Bj\u00f6rn Ambrosius received travel grants from Novartis, not related to this manuscript. R. Gold has received consultation fees and speaker honoraria from Bayer Schering, Biogen idec, Merck Serono, Novartis, Sanofi-Aventis, and TEVA. He also acknowledges grant support from Bayer Schering, Biogen idec, Merck Serono, Sanofi-Aventis, and TEVA, none related to this manuscript. Min-Suk Yoon has received speaker honoraria from CSL Behring and Grifols, scientific grant from CSL Behring, none related to this manuscript. The other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"58"}}